- Integrated genomic and transcriptomic analysis identified KRT18 mutation and MTAP loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.Li, Zhiyong; Jin, Yinghui; Zou, Qingping; Shi, Xiaofeng; Li, Kaishu; He, Qun; Lin, Zhiying; Wang, Xiran; Xie, Sidi; Gao, Lei; Ni, Bowen; Zhang, Yunxiao; Wang, Ziyu; Liu, Rui; Liu, Yawei; Huang, Guanglong; Qi, SongtaoVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
- A phase II study of anlotinib combined with temozolomide in the treatment of patients with recurrent glioblastoma.Xu, Qingsheng; Chen, Qun; Zheng, Xiujue; Cai, Jinquan; Zhan, RenyaAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Aberrant Expression of N-Methylpurine-DNA Glycosylase Influences Patient Survival in Malignant GliomasCe, Liu; Yanyang, Tu; Jun, Yuan; Xinggang, Mao; Shiming, He; Liang, Wang; Guoqiang, Fu; Jianhai, Zong; Yongsheng, ZhangJOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY, 2012, 2012: 1-8.被引 3
会议论文
Mutational profiling of newly diagnosed glioblastoma to identify predictive biomarkers of efficacy and safety of anlotinib combination therapy.
3阅读
